Clinical trials: Normal Population
Bullous Pemphigoid
A Phase 2/3 Study of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid
ARGX-113-2009 is an operationally seamless 2-part, phase 2/3, prospective, global, multicenter, randomized, double-blinded, placebo-controlled study to investigate the efficacy, safety, tolerability, immunogenicity…
- Trial name
- BALLAD (NCT05267600)
- Testing
- efgartigimod PH20 SC, Prednisone
- Where
- 129 sites in United States, Australia and 19 more
- Volunteers
- 98 people
- Sponsor
- argenx
Inflammatory Rosacea
Study of 0444 Gel in the Treatment of Inflammatory Lesions of Rosacea
The aim of this trial is to assess the efficacy of Metronidazole Topical Gel 1% in the Treatment of Inflammatory Lesions of Rosacea.
- Trial name
- NCT01016782
- Testing
- 0444
- Volunteers
- 867 people
- Sponsor
- Fougera Pharmaceuticals Inc.
Breast Cancer
Study to Compare Zoladex™ 10.8 mg With Zoladex 3.6 mg in Pre-menopausal Women With Breast Cancer
The purpose of this study is to examine the efficacy and safety as well as the characteristics of the female hormone and study medications after administration in pre-menopausal women with estrogen receptor positive advanced…
- Trial name
- NCT01073865
- Testing
- ZD9393 (Zoladex) 10.8 mg, ZD9393 (Zoladex) 3.6 mg
- Where
- 55 sites in India, Japan and 4 more
- Volunteers
- 222 people
- Sponsor
- AstraZeneca
Alopecia Areata
A Study to Evaluate Efficacy and Safety of Deucravacitinib in Participants With Alopecia Areata
The purpose of this study is to evaluate the efficacy of deucravacitinib versus placebo at Week 24 and safety and tolerability of deucravacitinib versus placebo in adults with alopecia areata.
- Trial name
- NCT05556265
- Testing
- Deucravacitinib
- Where
- 28 sites in United States, Australia and 4 more
- Volunteers
- 94 people
- Sponsor
- Bristol-Myers Squibb
Impetigo
Safety and Efficacy of Topical NVC-422 Gel in Impetigo
This is a randomized, double-blind study comparing 0.1% NVC-422, 0.5% NVC-422 and 1.5% NVC-422 topical gel in children with impetigo.
- Trial name
- NCT01367314
- Testing
- NVC-422
- Where
- 2 sites in Dominican Republic
- Volunteers
- 129 people
- Sponsor
- NovaBay Pharmaceuticals, Inc.
Atopic Dermatitis
A Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and Infants With Moderate-to-severe Atopic Dermatitis
The purpose of this trial is to test whether treatment with tralokinumab (administered subcutaneous injections [SC]) in combination with topical corticosteroids (TCS) is safe and effective to treat moderate-to-severe atopic…
- Trial name
- TRAPEDS 2 (NCT06311682)
- Testing
- Tralokinumab + TCS
- Where
- 72 sites in United States, Belgium and 11 more
- Volunteers
- 195 people
- Sponsor
- LEO Pharma
Systemic Lupus Erythematosus
A Study Evaluating the Effects of GLPG3970 Given as Oral Treatment for 12 Weeks in Adults With Systemic Lupus Erythematosus
This is a first exploration of GLPG3970 in subjects with active systemic lupus erythematosus (SLE) to evaluate the effect on disease biomarkers and to determine its pharmacokinetics (PK) profile, safety and tolerability, and…
- Trial name
- TAPINOMA (NCT04700267)
- Testing
- GLPG3970 film-coated tablet
- Where
- 14 sites in Bulgaria, Moldova and 3 more
- Volunteers
- 11 people
- Sponsor
- Lakefront Biotherapeutics NV
Neutropenic Complications, Breast Neoplasms
Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Neulasta®
The study will assess the efficacy of LA-EP2006 compared to Neulasta® with respect to the mean duration of severe neutropenia during treatment with myelosuppressive chemotherapy in breast cancer patients.
- Conditions
- Neutropenic Complications, Breast Neoplasms, Chemotherapy-induced Neutropenia, Chemotherapeutic Toxicity
- Trial name
- PROTECT-1 (NCT01735175)
- Testing
- LA-EP2006, Neulasta®
- Where
- 41 sites in Brazil, India and 4 more
- Volunteers
- 316 people
- Sponsor
- Sandoz
Alopecia Areata
Efficacy and Tolerability Study of Two Dose Regimens of CTP-543 in Adults With Alopecia Areata
This study will evaluate the efficacy and tolerability of once-daily versus twice-daily dosing of CTP-543, in adult patients with chronic, moderate to severe alopecia areata.
- Trial name
- NCT03811912
- Testing
- CTP-543
- Where
- 10 sites in United States
- Volunteers
- 57 people
- Sponsor
- Concert Pharmaceuticals
Healthy Volunteers Eligible for Study; Drug Being Developed for Allergic Conjunctivitis
Safety Study of Ophthalmic Solution in Healthy, Normal Volunteers
The purpose of this study is to evaluate the safety of R89674 0.25% ophthalmic solution in healthy normal volunteers
- Trial name
- NCT00223951
- Testing
- R89674 (generic name not yet established)
- Where
- 6 sites in United States
- Volunteers
- 900 people, healthy volunteers welcome
- Sponsor
- Vistakon Pharmaceuticals
Onychomycosis
Clinical Trial on Onychomycosis With P-3058 Nail Solution in Pediatric Population
Pediatric patients affected by mild-to-moderate distal subungual onychomycosis (DSO) or affected by white superficial onychomycosis (WSO), due to dermatophytes, will be treated topically with P-3058 nail solution according to the…
- Trial name
- NCT02547701
- Testing
- P-3058
- Where
- 5 sites in Belgium, Germany and 3 more
- Volunteers
- 20 people
- Sponsor
- Polichem S.A.
Actinic Keratosis
Multicenter, Double-blind, Placebo Controlled Comparing Test Fluorouracil Cream to Carac Cream in Actinic Keratosis
This study is to evaluate the efficacy and safety of a generic formulation of fluorouracil 0.5% cream against the brand product (Carac) in participants with actinic keratoses.
- Trial name
- NCT02616601
- Testing
- Generic Fluorouracil Cream, Carac® (Fluorouracil) Cream, Vehicle Cream
- Where
- 17 sites in United States
- Volunteers
- 422 people, healthy volunteers welcome
- Sponsor
- Actavis Inc.
Breast Cancer, Breast Neoplasms
Trial to Compare the Safety, Efficacy and Immunogenicity of TX05 With Herceptin® in HER2+ Early Breast Cancer
This is a Phase III, double-blind, randomized, multicenter study to compare the efficacy and to evaluate the safety and immunogenicity of TX05 (trastuzumab) with Herceptin® in subjects with HER2 positive early breast cancer.
- Conditions
- Breast Cancer, Breast Neoplasms, HER2-positive Breast Cancer, Stage II Breast Cancer
- Trial name
- NCT03556358
- Testing
- TX05 (trastuzumab), Herceptin®, Paclitaxel
- Where
- 146 sites in Belarus, Chile and 8 more
- Volunteers
- 809 people
- Sponsor
- Tanvex BioPharma USA, Inc.
Atopic Dermatitis (AD)
PRA-216 Atopic Dermatitis Safety and Efficacy Study
This study will evaluate the safety, tolerability, pharmacokinetics and immunogenicity of PRA-216 compared to placebo in patients with moderate to severe Atopic Dermatitis (AD)
- Trial name
- NCT07810777
- Testing
- Active PRA-216
- Where
- 9 sites in Australia, New Zealand
- Volunteers
- 39 people
- Sponsor
- Prana Therapies Inc
Infertility
Phase III Study Comparing Efficacy and Safety of AFOLIA vs Gonal-f® RFF in Women (35 to 42) Undergoing IVF
The purpose of this study is to show that AFOLIA, a recombinant manufactured human follicle stimulating hormone (r-hFSH) has a similar efficacy and safety profile compared to Gonal-f® RFF.
- Trial name
- NCT01687712
- Testing
- AFOLIA, Gonal-f® RFF
- Where
- 22 sites in United States
- Volunteers
- 1,100 people
- Sponsor
- Fertility Biotech AG
Actinic Keratosis
Study to Determine the Safety of Two Applications of PEP005 Topical Gel to Actinic Keratoses
The purpose of this study is to determine whether topical application of PEP005 is safe for the treatment of actinic keratoses.
- Trial name
- NCT00107965
- Testing
- PEP005
- Where
- 6 sites in Australia
- Volunteers
- 60 people
- Sponsor
- Peplin
Lupus Nephritis
A Study of QLG1074 Combined With Background Therapy in Subjects With Active Lupus Nephritis
The purpose of this study is to assess the efficacy of QL1074 compared with placebo in achieving renal response after 52 weeks of therapy in subjects with Active Lupus Nephritis.
- Trial name
- NCT06406205
- Testing
- Voclosporin（QL1074）
- Where
- 10 sites in China
- Volunteers
- 270 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Atopic Dermatitis
A Study to Learn About Abrocitinib Tablets in People With Atopic Dermatitis in India
The purpose of this clinical trial is to learn about the safety and how well the study medicine (called Abrocitinib) works for the potential treatment of moderate to severe Atopic Dermatitis (AD) in India.
- Trial name
- NCT05375929
- Testing
- Abrocitinib 100 mg, Abrocitinib 200 mg
- Where
- 15 sites in India
- Volunteers
- 200 people
- Sponsor
- Pfizer
Rheumatoid Arthritis
A Study to Evaluate Rituximab in Combination With Methotrexate in Methotrexate-Naive Patients With Active Rheumatoid Arthritis
This is a phase III, randomized, controlled, double-blind, parallel group, international study in approximately 750 patients with active Rheumatoid Arthritis (RA) who are naive to Methotrexate (MTX) therapy.
- Trial name
- IMAGE (NCT00299104)
- Testing
- folate, methotrexate, methylprednisolone
- Volunteers
- 755 people
- Sponsor
- Genentech, Inc.
Rosacea
Phase 3 Efficacy and Safety Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea
This is a Phase 3 efficacy and safety study of CD07805/47 topical gel in subjects with facial erythema associated with rosacea. The study hypothesis is that CD07805/47 gel, applied topically once daily is more efficacious than…
- Trial name
- NCT01355471
- Testing
- CD07805/47 Gel
- Where
- 15 sites in United States, Canada
- Volunteers
- 293 people
- Sponsor
- Galderma R&D
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.